Tetrathiomolybdate: all 30 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• A Study of Tetrathiomolybdate (TM) Plus CapecitabineRecruitingNCT06134375Phase 1/2
• Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy ParticipantsCompletedNCT05641311Phase 1Results posted
• A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy AdultsCompletedNCT05319912Phase 1Results posted
• A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy AdultsCompletedNCT05319899Phase 1Results posted
• Study of Oral ALXN1840 at 2 Dose Strengths in Healthy AdultsCompletedNCT05303324Phase 1Results posted
• Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson DiseaseTerminatedNCT05047523Phase 3Results posted
• Bioavailability Study of 2 Oral Formulations of ALXN1840CompletedNCT04610580Phase 1Results posted
• Copper Balance in Healthy Participants Administered ALXN1840CompletedNCT04594252Phase 1Results posted
• Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840CompletedNCT04573309Phase 2Results posted
• A Study of the Cardiac Effects of ALXN1840 in Healthy AdultsCompletedNCT04560816Phase 1Results posted
• Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy ParticipantsCompletedNCT04526210Phase 1Results posted
• Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.CompletedNCT04526197Phase 1Results posted
• Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840CompletedNCT04422431Phase 2Results posted
• Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson DiseaseTerminatedNCT03403205Phase 3Results posted
• Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease PatientsCompletedNCT02273596Phase 2Results posted
• Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast CancerTerminatedNCT00195091Phase 2Results posted
• Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal CarcinomaCompletedNCT00176800Phase 2Results posted
• Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung CancerCompletedNCT01837329Phase 1
• Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary CirrhosisCompletedNCT00805805Phase 3
• Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast CancerTerminatedNCT00674557Phase 2
• Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung CancerWithdrawnNCT00560495Phase 1
• Study of ATN-224 in Patients With Prostate CancerStatus unknownNCT00405574Phase 2
• Randomized Trial of ATN-224 and Temozolomide in Advanced MelanomaStatus unknownNCT00383851Phase 2
• A Study of ATN-224 and Bortezomib in Patients With Multiple MyelomaTerminatedNCT00352742Phase 1/2
• Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary FibrosisCompletedNCT00189176Phase 1/2
• Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal CarcinomaCompletedNCT00176774Phase 2
• Tetrathiomolybdate in Hormone Refractory Prostate CancerCompletedNCT00150995Phase 2
• A Study of Tetrathiomolybdate in the Treatment of Psoriasis VulgarisCompletedNCT00113542Phase 2
• Treatment of Hepatocellular Carcinoma With TetrathiomolybdateCompletedNCT00006332Phase 2
• Study of Tetrathiomolybdate in Patients With Wilson DiseaseCompletedNCT00004339Phase 3

← Tetrathiomolybdate overview